Bausch Health Americas
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bausch Health Americas sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Bausch Health Americas: 168 sponsored US clinical trials, 6 recruiting.
Bausch Health Americas sponsors 168 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 144 completed. 86 of these trials are in Phase 3-4 (later-stage) and 68 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 6 trials.
Top-decile sponsor footprint
Bausch Health Americas ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
144 of 157 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 2 of 4
Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
NCT03058744
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability
NCT03063489
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
NCT02387359
One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
NCT02240108
A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
NCT02173392
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
NCT02240121
12-Week Study of Plecanatide for CIC (The National CIC3 Study)
NCT02122471
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
NCT02024646
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
NCT02029495
Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris
NCT02849860
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
NCT02045277
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
NCT02047604
EYEFILL® C. -US Viscoelastic Clinical Investigation
NCT02024711
12-Week Study of Plecanatide for CIC (The CIC3 Study)
NCT01982240
Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)
NCT01983306
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
NCT01937260
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
NCT01919697
Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
NCT01904409
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
NCT01846663
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
NCT01842581
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
NCT01722318
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
NCT01701024
Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects
NCT01705938
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
NCT01708629
Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
NCT01708590
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
NCT01708603
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
NCT01647906
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
NCT01543178
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
NCT01532648
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
NCT01429987
AMG 827 in Subjects With Psoriatic Arthritis
NCT01516957
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
NCT01427296
Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
NCT01374490
The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis
NCT01349673
A Study of a New Drug Treatment for Acne
NCT01326780
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
NCT01313728
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
NCT01186770
Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea
NCT01177410
A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease
NCT01149811
Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects
NCT01366326
A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa
NCT01140841
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
NCT01127503
Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
NCT01101100
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
NCT01053962
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
NCT01007448
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
NCT01008423
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
NCT01008410
Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face
NCT00952523
Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face
NCT00919191
A Study of Different Use Regimens Using Two Acne Treatments
NCT00907257
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 37 |
| Phase 3 | 68 |
| Phase 4 | 18 |
What is open in the Bausch Health Americas pipeline
6 recruiting of 168 indexed (4% open); 144 completed (86%).
Phase mix: 86 late (III/IV) vs 68 early (I/II) (balanced across stages).
Top condition: Acne Vulgaris (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bausch Health Americas: open-pipeline peers nationwide
Peers matched on 168 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bausch Health Americas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- Sumitomo Pharma America · 168 trials · 4% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Bayer · 4% recruiting · 591 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
Related
What to do with this Bausch Health Americas page
168 registered trials is a research-attention snapshot, not an endorsement of Bausch Health Americas or any single study.
- 6 of Bausch Health Americas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Bausch Health Americas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bausch Health Americas pipeline card: 168 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.